There could soon be a new weapon in the fight against canine cancer. Researchers at the University of Missouri College of Veterinary Medicine are set to begin testing of an anti-cancer drug in dogs this fall. University of Missouri Assistant Professor of Oncology Kimberly Selting, DVM, DACVIM, will lead the research. Selting said the clinical trial will include 15 dogs, and she will start enrolling patients in mid-October. “The study will allow any dog with a confirmed diagnosis of cancer, and that has a tumor that is still measureable,” Selting said. “We will note if any particular cancers respond better than others and that will help us design the next phase of this clinical research, knowing which kinds of cancer to target. In people, taxanes are used often for lung and intestinal cancers, as well as breast and other cancers.”